2019
Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis
Gupta A, Hannan A, Maini R, Bitner S, Stone S, Regmi M, Tobian A, Josephson C, Krishnamurti L, Takemoto C, Goel R. Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis. Blood 2019, 134: 4711. DOI: 10.1182/blood-2019-123161.Peer-Reviewed Original ResearchCongestive heart failureNationwide Inpatient SampleMedian hospital chargesHepatitis CMedian ageHIV/AIDSHospital dischargeInpatient mortalityHeart failureCommon diagnosisHealthcare utilizationHaemophilia patientsHospital chargesMortality rateHemophilia AUtilization Project Nationwide Inpatient SampleYounger ageCommon discharge diagnosesMost hemophilia patientsNon-bleeding complicationsInpatient mortality rateHepatitis C casesCentral line infectionsCoronary artery diseaseInsurance coverage
2012
Mortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimates
GOEL R, KRISHNAMURTI L. Mortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimates. Haemophilia 2012, 18: 688-692. PMID: 22500777, DOI: 10.1111/j.1365-2516.2012.02774.x.Peer-Reviewed Original ResearchConceptsNational Inpatient SampleCentral line infectionsHospital mortalityHospital dischargeLine infectionsHemophilia AMean hospital chargesCause of hospitalizationHealth care utilizationGeneral male populationDiagnosis of hemophiliaAge-related illnessesStratified probability sampleHepatitis CRespiratory failureHeart failureIntraventricular hemorrhageMedian ageAge of mortalityCare utilizationHospital chargesIntracranial hemorrhageNeonatal periodPediatric deathsHepatic coma
2007
Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).
Dale J, Price S, Tretler J, Aldridge P, Montague S, Davis J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Puck J, Fleisher T, Rao V. Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS). Blood 2007, 110: 1319. DOI: 10.1182/blood.v110.11.1319.1319.Peer-Reviewed Original ResearchAutoimmune lymphoproliferative syndromeALPS patientsMycophenolate mofetilRituximab therapyDouble-negative T lymphocytesALPS phenotypeNegative T lymphocytesUse of rituximabCompletion of therapyRed cell transfusionAdult male patientsNIH Clinical CenterLong-term riskDurable normalizationPneumococcal sepsisPrednisone pulsesRefractory ITPRituximab infusionRituximab useWeekly vincristineCell transfusionHepatitis CImmune thrombocytopeniaPalpable spleenPolysaccharide vaccine
2005
Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities.
Ambrusko S, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities. Blood 2005, 106: 3791. DOI: 10.1182/blood.v106.11.3791.3791.Peer-Reviewed Original ResearchSickle cell diseasePulmonary hypertensionCell diseaseSilent strokeHepatitis CClinical characteristicsAplastic crisisCerebrovascular diseaseTransfusion therapyNocturnal enuresisTR jetTricuspid regurgitant jet velocityChronic transfusion programMoya-Moya syndromeTR jet velocityAcute chest syndromeElevated total bilirubinRestrictive lung diseaseMajority of patientsObstructive sleep apneaRegurgitant jet velocityCell-directed therapiesMiddle cerebral arteryRetrospective case reviewSickle cell patients